Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Always Moving Foward

Don’t Let PainPut Your Life On Hold

Recognized as a global leader in hyaluronic acid technology, and for always pioneering what’s next, Fidia offers patients much more than pain relief solutions – we offer hope to live better.

Our Products

Hymovis

The industry’s only 2-injection hyaluronic acid treatment for osteoarthritis (OA) knee pain

Visit Site
Triluron

A new 3-injection hyaluronic acid treatment for osteoarthritis (OA) knee pain

Visit Site
Hyalgan

The original safe, proven hyaluronic acid treatment for osteoarthritis (OA) knee pain

Visit Site
NuDYN

An acellular, shelf-stable, amniotic membrane-derived injectable allograft, which retains rich intrinsic beneficial properties of the amniotic membrane

Visit Site
CartiJoint

A natural over-the-counter dietary supplement

Visit Site
HyaloGyn

A hyaluronic acid-based gel that provides temporary relief of vaginal dryness symptoms

Visit Site

Recent Company News

To all Partners, Customers, Suppliers,

According to Fidia Farmaceutici S.p.A mission and policy, health and safety of people, and of course of our employees, are absolute priority. This is why we decided to reduce potential risks, asking our colleagues, partners, visitors, ecc… to work remotely as much as possible, as well as to strictly follow all the rules our Government has recently published.

As a consequence, we are either postponing or organizing meetings to take place digitally, in order to guarantee usual working activities, until the risk of infection is minimized

This is not affecting our working activities, thus we guarantee full operations in, from and to the factories. Also, all transports of goods, in Italy and to foreign countries are guaranteed and operations proceed at normal capacity/as planned. In addition to this, at present we do not foresee any issue related to the supply of materials from our suppliers.

We are sure you all agree on the precautions we are taking in this emergency period, and we will share updates when new information or guidelines need to be communicated.

Best regards

Carlo Pizzocaro
CEO Fidia Farmaceutici S.p.A.

Are you sure you want to navigate away from this page?

Click OK to continue or Cancel to stay on current page.

Okay Cancel